Cross Talk: Case Conferences From MGH
Recently published articles about Cross Talk: Case Conferences From MGH
Cross Talk: Case Conferences From MGH
A 65-Year-Old Man With Amyotrophic Lateral Sclerosis and Psychiatric Distress
December 13, 2023
This case shows the psychological and pharmacologic aspects of providing tailored care for a patient with ALS. The authors discuss how these approaches impacted the patient and how ALS-specific...
Cross Talk: Case Conferences From MGH
Pharmacotherapy and Ketamine Assisted Psychotherapy for Treatment-Resistant Depression
April 5, 2023
A 61-year-old patient with TRD and a history of self-criticism sought ketamine assisted psychotherapy. Experts from diverse therapeutic perspectives discuss this intriguing case.
Cross Talk: Case Conferences From MGH
Treatment of Overthinking: A Multidisciplinary Approach to Rumination and Obsession Spectrum
July 6, 2022
Six clinicians from different disciplines discuss the case of a woman who, after 20 years, finally achieved symptom relief when her primary complaint of “labored thinking” was targeted specifically.
Cross Talk: Case Conferences From MGH
Psychological Dimensions of Palliative Care Consultation
February 22, 2022
This compelling case presentation illustrates the challenges of providing palliative care during the pandemic. The expert discussion that follows examines the case from various perspectives and suggests ways clinicians...
Recent JCP Articles on Cross Talk: Case Conferences From MGH
Recent PCC Articles on Cross Talk: Case Conferences From MGH
Original Research
Global Research Trends in Community Psychiatry
June 2, 2026
This bibliometric analysis identifies the practice-relevant areas most emphasized in the “community psychiatry” literature (2015–2025), which clinicians can use to prioritize local quality improvement targets aligned with current service...
Featured Cross Talk: Case Conferences From MGH Research
Commentary
Prescribing GLP-1 Receptor Agonists for Persons With Mental Disorders: Evidence-Based and Aspirational Targets
June 1, 2026
Evidence-based prescription of GLP-1 RAs in persons with serious mental illness and/or substance use disorders holds promise to improve their health and wellbeing and possibly reduce excess mortality.